Kirsty (previously Kixelle)
Country: Unjoni Ewropea
Lingwa: Olandiż
Sors: EMA (European Medicines Agency)
Fuljett ta 'informazzjoni
(PIL)
01-12-2023
Karatteristiċi tal-prodott
(SPC)
01-12-2023
Rapport ta 'Valutazzjoni Pubblika
(PAR)
14-09-2021
Ingredjent attiv:
insuline aspart
Disponibbli minn:
Biosimilar Collaborations Ireland Limited
Kodiċi ATC:
A10AB05
INN (Isem Internazzjonali):
insulin aspart
Grupp terapewtiku:
Geneesmiddelen die worden gebruikt bij diabetes
Żona terapewtika:
Suikerziekte
Indikazzjonijiet terapewtiċi:
Kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Sommarju tal-prodott:
Revision: 4
L-istatus ta 'awtorizzazzjoni:
Erkende
Data ta 'l-awtorizzazzjoni:
2021-02-05
Fuljett ta 'informazzjoni
SERVER ERROR 404 - FILE OR DIRECTORY NOT FOUND. THE RESOURCE YOU ARE LOOKING FOR MIGHT HAVE BEEN REMOVED, HAD ITS
NAME CHANGED, OR IS TEMPORARILY UNAVAILABLE.
Aqra d-dokument sħiħ
Karatteristiċi tal-prodott
SERVER ERROR 404 - FILE OR DIRECTORY NOT FOUND. THE RESOURCE YOU ARE LOOKING FOR MIGHT HAVE BEEN REMOVED, HAD ITS
NAME CHANGED, OR IS TEMPORARILY UNAVAILABLE.
Aqra d-dokument sħiħ
